机构名称：
¥ 1.0
sørenTulstrup，总裁兼首席执行官Hansa Biopharma说：“ Hansa进入2024年，处于强大的位置，可以成功执行我们的关键优先事项。I am particularly encouraged by the strong commercial performance of Idefirix ® in the fourth quarter of 2023 and the continued progress we have achieved across our pipeline, with positive phase 2 data read-outs in several potential new indications for imlifidase as well as a positive first-in-human trial of HNSA-5487, Hansa's lead candidate in the Novel Immunoglobulin Cleaving Enzymes for Repeat Dosing (NiceR) 程序。，我们还通过与MENA地区的Newbridge建立新的商业合作伙伴关系，继续扩展对高度敏感的肾脏移植患者的Imlifidase访问权限。最终，在2023年12月，首次使用Imlifidase的临床研究是对Duchenne肌肉营养不良（DMD）中Sarepta的SRP-9001基因治疗的预处理。”
新闻稿
主要关键词
相关文件推荐
